ArticleBlood2023

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Sylvie D Freeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.